Adicet Bio's Cancer Candidate Shows Anti-Tumor Activity In Preclinical Study
Portfolio Pulse from Vandana Singh
Adicet Bio announced preclinical data for ADI-270, an allogeneic gamma delta CAR T cell therapy candidate targeting CD70+ cancers. The data showed anti-tumor activity, significant inhibition of tumor growth, and improved resistance to killing by host T cell rejection.
May 18, 2023 | 6:18 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Adicet Bio's ADI-270 demonstrated anti-tumor activity in preclinical study, targeting CD70+ cancers. The stock price is down 6.01% at $6.27.
The preclinical data for ADI-270 is positive, showing anti-tumor activity and significant inhibition of tumor growth. However, the stock price is down 6.01% at $6.27, indicating that the market may have already priced in the news or is reacting to other factors. The impact on the stock price in the short term is neutral, as the positive news may be offset by other factors.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100